Infertility  >>  Ovidrel (choriogonadotropin alfa)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

6 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ovidrel (choriogonadotropin alfa) / EMD Serono
NCT00505752: Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)

Completed
2
520
US
AS900672-Enriched 50 microgram (mcg), Hyperglycosylated r-hFSH, AS900672-Enriched 100 mcg, AS900672-Enriched 150 mcg, Follitropin alfa 150 international unit (IU), Gonal-f®, Follicle stimulating hormone (FSH), Recombinant human chorionic gonadotropin (r-hCG), Ovidrel®, Choriogonadotropin alfa
Merck KGaA, Darmstadt, Germany
Infertility
09/08
09/08
NCT01079949 / 2006-005268-19: A Phase II Study to Assess the Efficacy and Safety of Luveris® (Lutropin Alfa) in Mid Follicular Phase for Controlled Ovarian Stimulation (COS) in Advanced Reproductive Age

Terminated
2
93
Europe
r-hLH + r-hFSH, Luveris®, Lutropin alfa, r-hFSH, Recombinant Human Choriogonadotropin (r-hCG), Ovitrelle®, GnRH antagonist, Cetrotide®
Merck KGaA, Darmstadt, Germany, Merck, S.L., Spain
Infertility, Ovulation Induction
10/10
10/10
EMR700642-606, NCT01029470: To Describe the Effect of rhLH Supplementation in Women With Hyporesponse to rhFSH After Pituitary Downregulation

Unknown status
2
150
RoW
Luveris, Gonal-f, ovidrel
Peking University Third Hospital, Peking Union Medical College Hospital, Chongqing Health Center for Women and Children, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, Reproductive & Genetic Hospital of CITIC-Xiangya
Infertility
10/10
03/11
2022-000753-80: Clinical research study to learn about the effect and safety of different doses of FE 999302 when given as a single dose for final development of the eggs after ovarian stimulation Estudio de investigación clínica para conocer el efecto y la seguridad de diferentes dosis de FE 999302 cuando se administra como dosis única para el desarrollo final de los óvulos después de la estimulación ovárica

Ongoing
2
500
Europe
NOVAREL, OVITRELLE, FE 999302, FE 999086, Solution for injection, Powder and solvent for solution for injection, Solution for injection in pre-filled pen, Solution for injection in pre-filled syringe, NOVAREL, OVITRELLE
Ferring Pharmaceuticals A/S, Ferring Pharmaceuticals A(S
Infertility Infertilidad, Infertility Infertilidad, Body processes [G] - Reproductive physiologi cal processes [G08]
 
 
TIFFANY, NCT05571111: Clinical Research Study to Learn About the Effect and Safety of Different Doses of FE 999302 When Given as a Single Dose for Final Development of the Eggs After Ovarian Stimulation

Withdrawn
2
0
Europe
FE 999302, recombinant hCG, Ovitrelle, Novarel
Ferring Pharmaceuticals
Infertility
03/24
06/24
CS-EOSP-ICSI, NCT04071574: Comparative Study on the Efficacy of Ovarian Stimulation Protocols on the Success Rate of ICSI in Female Infertility

Completed
1/2
200
RoW
Human Chorionic Gonadotropin (hCG), OVITRELLE / PREGNYL, Gonadotropins, MENOPUR, GNRH-A Triptorelin, DECAPEPTYL, GnRH antagonist, CETROTIDE / ORGULATRON
Lebanese University
Female Infertility, Female Infertility Due to Ovulatory Disorder, Premature Ovarian Failure, Polycystic Ovary Syndrome, Female Infertility of Tubal Origin, Ectopic Pregnancy, Salpingitis, Female Infertility Due to Tubal Block, Female Infertility Due to Tubal Occlusion, Hydrosalpinx, Female Infertility - Cervical/Vaginal, Female Infertility Endocrine, Endometriosis, Fibroids, Congenital Uterine Anomaly, Infections Uterine, Female Infertility of Other Origin
08/19
05/23

Download Options